<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01251211</url>
  </required_header>
  <id_info>
    <org_study_id>BOTNEP</org_study_id>
    <nct_id>NCT01251211</nct_id>
  </id_info>
  <brief_title>Botulinum Toxin in Peripheral Neuropathic Pain</brief_title>
  <official_title>Randomized Double Blind Placebo Controlled Multicenter Study of the Efficacy and Safety of Repeated Administrations of Botulinum Toxin Type A (Botox) in the Treatment of Peripheral Neuropathic Pain</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital Ambroise Paré Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospital Ambroise Paré Paris</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Pain due to peripheral nerve lesion remains extremely difficult to treat and current
      treatments have onl moderate efficacy and/or side effects. The investigators have previously
      demonstrated the long term efficacy of Botulinum toxin type A (BTX-A) in a small group of
      patients with post-traumatic/postherpetic neuralgia and allodynia. The present study aims to
      a/ confirm the efficacy of repeated applications of BTX-A in a larger group of patients with
      peripheral neuropathic pain with or without allodynia(primary outcome) ; b/ evaluate its
      mechanisms of action ; c/analyse the predictors of response ;d/analyse whether the second
      injection is associated with a therapeutic gain. This will be a randomized placebo controlled
      study. A total of 30 patients will be randomized to receive either BTX-A (subcutaneous
      injection in the painful area) or placebo. Each injection will be repeated within at least 3
      months depending on the duration of efficacy. Skin punch biopsies will be performed before
      and 1 month after BTX-A administration. The investigators postulate that this study will
      confirm the clinical efficacy and good safety of repeated administrations of BTX-A in the
      treatment of peripheral neuropathic pain.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2010</start_date>
  <completion_date type="Actual">January 2014</completion_date>
  <primary_completion_date type="Actual">January 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Average pain intensity on numerical scales in a self diary by the patient</measure>
    <time_frame>every day from baseline for up to 6 months</time_frame>
    <description>Numerical scales (0-10)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Efficacy of treatment on neuropathic symptoms</measure>
    <time_frame>at each visit</time_frame>
    <description>Neuropathic Pain Symptom Inventory will be used to assess symptoms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life VAS</measure>
    <time_frame>at each visit</time_frame>
    <description>This will be assessed using the EuroQol questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intensity of allodynia to brush</measure>
    <time_frame>at each visit</time_frame>
    <description>This will performed using a brush</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>assessment of effects of BTX-A on substance P and CGRP</measure>
    <time_frame>at baseline and 1 month after BTX-A or placebo</time_frame>
    <description>This will be performed using skin punch biopsies in the painful area</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Side effects</measure>
    <time_frame>throughout the study and each each visit</time_frame>
    <description>side effects of BTX-A will be assessed</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Detection and pain thresholds to mechanical and thermal stimuli and responses to suprathreshold stimuli</measure>
    <time_frame>at each visit</time_frame>
    <description>this will use quantitative sensory testing (thermotest, Von Frey filaments)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Predictors of the response</measure>
    <time_frame>Up to 6 months</time_frame>
    <description>We will assess the predictors of the response to BTX-A based on baseline pain thresholds, presence and severity of allodynia, skin punch biopsy and catastrophizing</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Evaluate the therapeutic gain of the second injection</measure>
    <time_frame>Throughout the study up to 6 months</time_frame>
    <description>Evaluate whether the second injection is associated with significant therapeutic gain on average pain intensity over 6 months</description>
  </other_outcome>
  <other_outcome>
    <measure>Evaluate pain relief at 24 weeks</measure>
    <time_frame>24 weeks</time_frame>
    <description>pain relief scale</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">66</enrollment>
  <condition>Postherpetic Neuralgia</condition>
  <condition>Diabetic Polyneuropathies</condition>
  <condition>Other Polyneuropathies</condition>
  <arm_group>
    <arm_group_label>botulinum toxin type A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>botulinum toxin type A will be injected subcutaneously in the painful area (maximum 300 units)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>sodium chloride 9 %</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>sodium chloride 9 % will be used as a neutral placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>botulinum toxin type A</intervention_name>
    <description>BTX A : 5 units/0.2 ml, maximum 300 units will be injected subcutaneous in the painful area ; this will be performed after randomization and within a minimum of 3 months interval depending on the duration of efficacy (maximum 6 months) Saline will be injected in the same volume in the painful area within the same frequency</description>
    <arm_group_label>botulinum toxin type A</arm_group_label>
    <arm_group_label>sodium chloride 9 %</arm_group_label>
    <other_name>botox</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Men or women aged 18 to 85 years Spontaneous pain with a minimal intensity of 4/10 on
        numerical scle Pain present for at least 6 months Pain related to painful mononeuropathy or
        sensory polyneuropathy Able to understand the protocol and comply to the requirements of
        the study Written informed consent Painful area limited to a maximum of 240 cm2

        Exclusion Criteria:

        Facial pain Litigation (pending) Unstable condition responsible for neuropathic pain (ie,
        unstable immunological disease...) HIV or chemotherapy induced neuropathy Contraindications
        to BTX-A (neuromuscular disease, hypersensitivity, infection, coagulation disorder,
        pregnancy) Other pain more severe than neuropathic pain No compliance with the self diary
        Drug abuse or alcoholism Severe major depression Cognitive impairment Other research
        protocol within the last 30 days
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nadine ATTAL, MD PhD</last_name>
    <role>Study Director</role>
    <affiliation>APHP and INSERM</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Divisão de Clínica Neurológica do Hospital das Clínicas da FMUSP</name>
      <address>
        <city>Sao Paulo</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Ambroise Paré, APHP</name>
      <address>
        <city>Boulogne-Billancourt</city>
        <zip>92100</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Dupuytren</name>
      <address>
        <city>Limoges</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
    <country>France</country>
  </location_countries>
  <verification_date>March 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 30, 2010</study_first_submitted>
  <study_first_submitted_qc>November 30, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 1, 2010</study_first_posted>
  <last_update_submitted>March 10, 2016</last_update_submitted>
  <last_update_submitted_qc>March 10, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 11, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hospital Ambroise Paré Paris</investigator_affiliation>
    <investigator_full_name>Nadine ATTAL</investigator_full_name>
    <investigator_title>Clinical principal investigator</investigator_title>
  </responsible_party>
  <keyword>BOTULINUM TOXIN</keyword>
  <keyword>NEUROPATHIC PAIN</keyword>
  <keyword>RANDOMIZED CONTROLLED TRIAL</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neuralgia</mesh_term>
    <mesh_term>Polyneuropathies</mesh_term>
    <mesh_term>Neuralgia, Postherpetic</mesh_term>
    <mesh_term>Diabetic Neuropathies</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Botulinum Toxins</mesh_term>
    <mesh_term>Botulinum Toxins, Type A</mesh_term>
    <mesh_term>onabotulinumtoxinA</mesh_term>
    <mesh_term>abobotulinumtoxinA</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

